Biomedical Engineering Reference
In-Depth Information
40. Ishida T, Kiwada H (2008) Accelerated blood clearance (ABC) phenomenon upon repeated
injection of PEGylated liposomes. Int J Pharm 354:56-62
41. Xu H, Wang KQ, Deng YH, da Chen W (2010) Effects of cleavable PEG-cholesterol
derivatives on the accelerated blood clearance of PEGylated liposomes. Biomaterials
31:4757-4763
42. Hatakeyama H, Akita H, Ito E, Hayashi Y, Oishi M, Nagasaki Y, Danev R, Nagayama K, Kaji
N, Kikuchi H, Baba Y, Harashima H (2011) Systemic delivery of siRNA to tumors using a
lipid
nanoparticle
containing
a
tumor-specific
cleavable PEG-lipid. Biomaterials
32:4306-4016
43. Kubetzko S, Sarkar CA, Pluckthun A (2005) Protein PEGylation decreases observed target
association rates via a dual blocking mechanism. Mol Pharmacol 68:1439-1454
44. Yamaoka T, Tabata Y, Ikada Y (1994) Distribution and tissue uptake of poly(ethylene glycol)
with different molecular weights after intravenous administration to mice. J Pharm Sci
83:601-606
45. Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ (1999) Therapeutic antibody
fragments with prolonged in vivo half-lives. Nat Biotechnol 17:780-783
46. Kubetzko S, Balic E, Waibel R, Zangemeister-Wittke U, Pluckthun A (2006) PEGylation and
multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor
targeting. J Biol Chem 281:35186-35201
47. Andresen H, Bier FF (2009) Peptide microarrays for serum antibody diagnostics. Methods Mol
Biol 509:123-134
48. Yoshimoto K, Nishio M, Sugasawa H, Nagasaki Y (2010) Direct observation of adsorption-
induced inactivation of antibody fragments surrounded by mixed-PEG layer on a gold surface.
J Am Chem Soc 132:7982-7989
49. Uchida K, Otsuka H, Kaneko M, Kataoka K, Nagasaki Y (2005) A reactive poly(ethylene
glycol) layer to achieve specific surface plasmon resonance sensing with a high S/N ratio: the
substantial role of a short underbrushed PEG layer in minimizing nonspecific adsorption. Anal
Chem 77:1075-1080
50. Yu D, Peng P, Dharap SS, Wang Y, Mehlig M, Chandna P, Zhao H, Filpula D, Yang K,
Borowski V, Borchard G, Zhang Z, Minko T (2005) Antitumor activity of poly(ethylene
glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo. J Control Release
110:90-102
51. Chabot GG (1997) Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33:245-259
52. Zhao H, Rubio B, Sapra P, Wu D, Reddy P, Sai P, Martinez A, Gao Y, Lozanguiez Y, Longley
C, Greenberger LM, Horak ID (2008) Novel prodrugs of SN38 using multiarm poly(ethylene
glycol) linkers. Bioconjug Chem 19:849-859
53. Pastorino F, Loi M, Sapra P, Becherini P, Cilli M, Emionite L, Ribatti D, Greenberger LM,
Horak ID, Ponzoni M (2010) Tumor regression and curability of preclinical neuroblastoma
models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor. Clin Cancer Res
16:4809-4821
54. Hershfield MS (1995) PEG-ADA: an alternative to haploidentical bone marrow transplanta-
tion and an adjunct
to gene therapy for adenosine deaminase deficiency. Hum Mutat
5:107-112
55. Burns CM, Wortmann RL (2011) Gout therapeutics: new drugs for an old disease. Lancet
377:165-177
56. Laden JC, Philibert P, Torreilles F, Pugni`re M, Martineau P (2002) Expression and folding of
an antibody fragment selected in vivo for high expression levels in
Escherichia coli
cytoplasm.
Res Microbiol 153:469-474
57. Jayson GC, Parker GJ, Mullamitha S, Valle JW, Saunders M, Broughton L, Lawrance J,
Carrington B, Roberts C, Issa B, Buckley DL, Cheung S, Davies K, Watson Y, Zinkewich-
P´otti K, Rolfe L, Jackson A (2005) Blockade of platelet-derived growth factor receptor-beta
by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated
with increased tumor vascularized volume. J Clin Oncol 23:973-981
